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Abstract
Background: Fermentation of dietary fiber in the colon results in the production of short chain fatty acids (mainly
propionate, butyrate and acetate). Butyrate modulates a wide range of processes, but its mechanism of action is mostly
unknown. This study aimed to determine the effects of butyrate on the transcriptional regulation of human colonic mucosa
in vivo.
Methodology/Principal Findings: Five hundred genes were found to be differentially expressed after a two week daily
butyrate administration with enemas. Pathway analysis showed that the butyrate intervention mainly resulted in an
increased transcriptional regulation of the pathways representing fatty acid oxidation, electron transport chain and
oxidative stress. In addition, several genes associated with epithelial integrity and apoptosis, were found to be differentially
expressed after the butyrate intervention.
Conclusions/Significance: Colonic administration of butyrate in concentrations that can be achieved by consumption of a
high-fiber diet enhances the maintenance of colonic homeostasis in healthy subjects, by regulating fatty acid metabolism,
electron transport and oxidative stress pathways on the transcriptional level and provide for the first time, detailed
molecular insight in the transcriptional response of gut mucosa to butyrate.
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Introduction
Short-chain fatty acids (SCFAs) are derived from the microbial
fermentation of undigested dietary fibers in the colon. As micro-
organisms preferably ferment carbohydrates, most saccharolytic
fermentation occurs in the proximal colon. Depletion of
carbohydrate sources in the distal colon leads to a switch from
saccharolytic to proteolytic fermentation, which is less favorable
due to the formation of potentially toxic products. Both these
toxic products and the lower availability of SCFAs in the distal
colon are hypothesized to be involved in the pathogenesis of
gastro-intestinal disorders such as ulcerative colitis (UC) and
cancer [1–3]. The amount of SCFAs (mainly acetate, propionate
and butyrate) produced in the colon depends on the site of
fermentation, the diet and the composition of the microbiota, and
can account for up to 5–15% of the total energy requirements of
humans [4]. Fecal concentrations of acetate, propionate and
butyrate are found in a molar ratio of approximately 60:20:20
[5,6], but limited data about luminal concentrations in specific
parts of the colon are only available from sudden death patients.
Due to rapid absorption and metabolism, actual concentrations
may differ. Among the different SCFAs, butyrate is known to
modulate numerous processes. It induces cell differentiation and
strongly inhibits cell proliferation in tumor cell lines [7–13].
Colonocytes use butyrate as their primary energy source and in
the absence of butyrate they undergo apoptosis, but opposite
effects were seen in transformed cells, suggesting a possible anti-
carcinogenic effect of butyrate [13–15]. Furthermore, butyrate
m a yh a v ea ne f f e c to ni n f l a m m a t i o n[ 1 3 ] ,o x i d a t i v es t r e s s[ 1 3 ] ,
intestinal barrier function [13,16,17], visceral perception and
rectal compliance [18] and may play a role in satiety [19,20].
Transcriptional responses of butyrate were studied mostly in cell
lines [14,15,21–32] and some studies were performed in animals
and human patients [3,30,33–35]. In vitro and animal studies
showed that butyrate downregulates the expression of genes
associated with proliferation and oxidative stress and upregulates
the expression of Mucin associated genes (Muc 1–4), tight junction
proteins (zonulin and occludin) and the butyrate transporter
monocarboxylate transporter-1 (MCT1). In UC patients, butyrate
was shown to increase the expression of the butyrate transporter
MCT-1 and to decrease inflammation by inhibition of the
activation of NF-kB. Effects of butyrate on global, genome-wide
transcriptional responses of human intestinal mucosa were not
described previously.
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6759The aim of this study was to determine the in vivo genome-wide
transcriptional response to local administration of butyrate in the
distal colon in healthy volunteers in order to identify the biological
processes mediated by butyrate, providing new leads for clinical
and mechanistic studies.
Materials and Methods
Objectives
To determine the in vivo transcriptional response of a local
administration of butyrate in the distal colon in healthy volunteers.
Participants
Sixteen healthy volunteers (12 females and 4 males, 18 to 62yrs)
participated in this study. Exclusion criteria were signs of bowel
dysfunction,gastrointestinalsurgery,ageover65years,oruseofany
medication, probiotics or prebiotics three months prior to inclusion,
were excluded from participation. All participants signed an
informed consent prior to participation to the study, which was
approved by the Ethical Committee of the University Hospital
Maastricht, the Netherlands, and conducted in full accordance with
the principles of the ‘Declaration of Helsinki’ (52
nd WMA General
assembly, Edinburgh, Scotland, Oct 2000). The study has been
registered in the US National Library of Medicine (http://www.
clinicaltrials.gov) with reference code NCT00693355.
Design
The study was performed according to a double-blind
randomized placebo-controlled cross-over design. The protocol
comprised of two experimental periods of two weeks each with a
wash-out period of two weeks in between (Figure 1). During each
experimental period, the subjects self-administered an enema
containing 100 mM of butyrate or placebo (60 ml, pH 7.0),
respectively, once daily prior to sleeping. The local hospital
pharmacy department prepared all enemas. The volunteers were
asked to defecate, if possible, prior to instillation of the enema. At
the end of each experimental period, a sigmoidoscopy was
performed in the morning after an overnight fast and biopsy
samples were taken from a standardized location in the sigmoid
colon (approx. 20 cm from the anal sphincter at the location of the
internal iliac artery). All sigmoidoscopy procedures were per-
formed in an unprepared colon to exclude possible effects induced
by the colon cleansing procedure. The diet was standardized 3
days prior to the sigmoidoscopy. After sampling, biopsies were
snap-frozen immediately in liquid nitrogen and stored at 280uC
until further analysis.
RNA extraction
RNA was isolated from frozen biopsies by adding a mixture of
1 ml Trizol (Invitrogen, Carlsbad, USA) and 10 ml b-mercapto-
ethanol, preheated up to 37uC. These mixtures were shaken for 30
seconds at maximum speed using a minibeadbeater. 200 ml
Chloroform was added and after 3 minutes of incubation, the
samples were centrifuged for 15 minutes, 21000 g at 4uC. 500 ml
was taken from the upper colorless phase and mixed with 500 ml
70% ethanol. RNA was further purified with an RNeasy mini kit
(Qiagen, Venlo, The Netherlands) combined with a DNase
treatment using the RNase-Free DNase set (Qiagen, Venlo, The
Netherlands) according to manufacturers protocol.
Quantity and purity of the RNA samples was determined using
the Nanodrop ND-1000 spectrophotometer (Nanodrop Technol-
ogies, Wilmington, USA) and RNA integrity was determined using
the Bioanalyzer 2100 (Agilent Technologies, Palo Alto, USA).
Microarray hybridization
Total RNA (150 ng) was amplified using the two-cycle cDNA
synthesis kit (Affymetrix, Santa Clara, USA) in combination with
the MEGAscript T7 in vitro transcription system (Ambion).
Double-stranded cDNA was biotin labeled with the GeneChip in
vitro transcription IVT labeling kit (Affymetrix, Santa Clara, USA).
Following fragmentation, 11 mg of biotin-labeled cRNA were
hybridized for 16 hour at 45uC on Affymetrix Human Genome
U133 Plus 2.0 Arrays.
GeneChips were washed and stained in the Affymetrix Inc.
Fluidics Station 450 (Affymetrix, Santa Clara, USA) and
hybridized. Cyclic RNA was detected using streptavidin coupled
to phycoerythrin. GeneChips were scanned using GeneChip
Scanner 3000/7G and GeneChip Operating System (GCOS,
Affymetrix, Santa Clara, USA) using Affymetrix default settings.
Microarray analysis
Images of the Human Genome U133 Plus 2.0 arrays were
quantified with GCOS software (Affymetrix). The chip description
file (CDF) used for the analysis was an update created and freely
distributed by the microarray lab of the university of Michigan
(http://brainarray.mbni.med.umich.edu) [36] based on UniGenes
(version 8). A more detailed description of this analysis is shown in the
supplementary data (Statistics S1). Briefly, the genes were analyzed
using a multivariate Gaussian linear regression including the
hybridization and labeling spikes, the hybridization day, and a
random effect to take into account multiple observations on the same
subject. The inference criterion used for comparing the models is
their ability to predict the observed data, i.e. models are compared
directly through their minimized minus log-likelihood. When the
numbers of parameters in models differ, they are penalized by adding
the number of estimated parameters, a form of the Akaike
Information Criterion (AIC) [37]. For each gene, the treatment
group was then added to the model. The gene under consideration
was found to be differentially expressed if the AIC decreased
compared to the model not containing the treatment effect. Effects
are considered significant if the 95% confidence intervals do not
overlap. This analysis method avoids multiple testing issues and
improves statistical power compared to the conventional approach.
Pathway analysis
The genes analyzed and fold changes were loaded into
GenMapp (http://genmapp.org) [38] and MAPPFinder [39]
software packages to evaluate the transcripts in relation to known
biological processes, molecular function and cellular component
based on Gene Ontology (GO) terms [40] and contributed maps
(i.e. local MAPPs). Only gene-transcripts with either their average
intensities for the control and treated groups above 250 or average
intensities for one of these groups above 500 and a 10 percent up
or down regulation fold change were used to obtain a ranked list of
pathways with differentially expressed genes.
Figure 1. Design of butyrate study in healthy volunteers.
doi:10.1371/journal.pone.0006759.g001
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relatively high numbers of differentially expressed genes. The
ranking of regulated pathways was indicated by the individual Z-
scores. The Z-score increases when higher numbers of changing
gene reporters relative to the number of genes on the MAPP are
found on MAPPs. All pathways with both the Z-score and the
number of genes changed.1 were considered to be significantly
regulated. The results of the pathway analysis are presented in GO
annotations (Table S1) and local MAPPs (Table S2), which give
a more precise representation of the biological pathways in which
the measured genes are involved.
Transcriptional data are published in the public database
‘‘ArrayExpress’’ [41] under accession number E-MEXP-1705.
Real-Time PCR
First strand cDNA was synthesized using the iScript cDNA
Synthese kit (Bio-Rad, Veenendaal, The Netherlands) according
to the manufacturer’s instructions. 500 ng of the total RNA used
for the microarray analysis was used as a template for the cDNA
reaction. The cDNA was diluted with RNase free H2Ot oa
concentration of 0.32 ng/ml. IQ Sybr Green Supermix (Bio-Rad,
Veenendaal, The Netherlands) was used for the Q-PCR. Each Q-
PCR reaction contained 12.5 ml iQ Sybr Green Supermix, 1 mlo f
10 mM gene-specific forward and reverse primers, 4 ml diluted
cDNA template and 6.5 ml sterile water. CANX, 18SrRNA and
GAPDH were included as Housekeeping genes. Primers that were
used are presented in Table 1.
Q-PCR reactions were run on the My IQ Single Color Real
Time PCR Detection System (Bio-Rad, Veenendaal, The Nether-
lands). After 3 minutes of incubation at 95uC, an amplification
cycle program of 40 cycles of 10 seconds at 95uC and 45 seconds
at 60uC, followed by a melting program was initiated.
Results
Micro-array analysis
We used microarray analysis to assess the expression levels of all
human genes in colonic biopsies after butyrate treatment
compared to placebo. In total, 501 genes were found to be
differentially expressed after the butyrate intervention compared
to placebo (Table S3). From those genes, 473 were up regulated
and 28 down regulated.
Pathway analysis
Pathway analysis with Genmapp software delivered a list of
significantly regulated pathways, ranked by z-score (Table S1
and S2). The butyrate intervention mainly regulated the citric
acid cycle (TCA-cycle) (Figure 2), fatty acid transport and
oxidation, electron transport (Figure 2), TNF-alpha signaling and
oxidative stress related pathways. In the TCA cycle pathway,
citrate synthase and some genes involved in the formation of a-
ketogluterate out of isocitrate were upregulated. In the pathway of
fatty acid metabolism, genes for transport and oxidation of
medium and long chain fatty acids were expressed differentially.
The pathway analyses also showed a number of differentially
expressed genes in the electron transport chain (Figure 2). Most
of these genes (9 out of 14) were present in Complex I and III of
the electron transport chain. In the oxidative stress pathway, a
number of genes involved in glutathione metabolism (GPX1,
GPX3 and GSR) were differentially expressed.
Validation of microarray analysis by q-PCR
Based on microarray- and pathway analyses, 6 genes of interest
were selected for confirmation by q-PCR. The increased
expression of Acadm, Gpx3, Gpx1 and Ndufa3, identified by
the micro array analysis, was confirmed by q-PCR (Table 2). The
gene reporters Ndufv1 and Gsr were upregulated in the micro
array, but downregulated in the q-PCR analysis.
Discussion
Local administration of butyrate in the distal colon resulted in
an increased transcription of genes, which were mainly associated
with energy metabolism, fatty acid metabolism and oxidative
stress. These results are in line with effects reported in literature, as
reviewed recently by our group [13]. We showed for the first time
that these processes are significantly regulated on the transcrip-
tional level by intraluminal butyrate in healthy humans.
The impact of the butyrate administration as presented in this
study with effects on gene transcription up to 39%, was lower
compared to previous findings in cell lines and animal studies,
probably due to the fact that butyrate was studied in healthy
volunteers in the most physiologically achievable way. Studying
humans in vivo gives a larger variance in study data due to
limitations of standardization as well as the genomic variability
compared to animal and in vitro studies. In contrast to stress models
in animals and patients suffering from gastrointestinal disorders,
healthy volunteers do not have a compromised gut. The beneficial
effects that can be expected from the present intervention are,
consequently, small compared to a compromised situation like in
animals, cell lines or patients. The concentration of butyrate used
in the present study (100 mM) was physiologically achievable by
Table 1. Genes that were selected for q-PCR analysis with the primers that were used.
Gene: Sequence ID Primer (forward, reverse):
18SrRNA M10098 GTAACCCGTTGAACCCCATT, CCATCCAATCGGTAGTAGCG
GAPDH NM_002046 TGCACCACCAACTGCTTAGC, GGCATGGACTGTGGTCATGAG
CANX NM_001024649 CCACTGCTCCTCCTTCATCTCC, CGGTATCGTCTTTCTTGGCTTTGG
ACADM NM_000016 GCCAGCGATGTTCAGATACTAGAGG, CCTTTCCAGGGCATACTTGGTAGC
GPX1 NM_000581 CCGACCCCAAGCTCATCACC, GATGTCAGGCTCGATGTCAATGG
GPX3 NM_002084 ACATGCCTACAGGTATGCGTGATTG, TGGAGTGGAGAACTGGAGAGAAAGG
GSR NM_000637 CAGGGACTTGGGTGTGATGAAATGC, GAGGTAGGGTGAATGGCGACTGTG
NDUFA3 NM_004542 GGAGACAAAGATGGCTGCGAGAG, GTCAGTGGAGGTGCTCACAGTTTC
NDUFV1 NM_007103 GCCATCGCCCGCCTCATTG, CCGTCACCCAGAGCACAAATCG
doi:10.1371/journal.pone.0006759.t001
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as used in some previous studies.
The microarray data show that fatty acid metabolism is
regulated by butyrate, as a number of genes associated with
processes involved in fatty acid transport, primary steps of beta
oxidation and the formation of keton bodies were regulated. The
transcription of genes encoding the fatty acid transporters
carnitine palmityl-CoA transferase 1 (CPT1) and carnitine-
acylcarnitine translocase (SLC25A20) was increased. CPT1 is
located in the outer mitochondrial membrane and promotes the
transport of long chain fatty acids into the mitochondrion by
binding carnitine to the fatty acids [42,43]. Transport of carnitine-
linked long chain fatty acids over the inner mitochondrial
membrane is facilitated by SLC25A20 in exchange for free
carnitine [44,45]. These two genes promote long chain fatty acid
transport from the cytosol to the mitochondrial matrix where b-
oxidation starts.
The first step of b-oxidation is the formation of 2-eonyl-CoA
from the corresponding saturated ester, catalyzed by SLC25A20.
For dehydrogenation of acyl-CoA, 4 enzymes are described, each
targeting fatty acids of a specific chain length: short-chain-acyl-
CoA dehydrogenase (ACADS, with C4 and C6 specificity),
medium- chain-acyl-CoA dehydrogenase (ACADM, with C4-
C12 specificity), long-chain-acyl-CoA dehydrogenase (ACADL,
active with C8-C20) and very-long-chain-acyl-CoA dehydroge-
nase (ACADVL, active with C12-C24) [43]. The butyrate (a C4
fatty acid) intervention resulted in an increased expression of both
ACADM (confirmed with q-PCR), located in the mitochondrial
matrix, and ACADVL, which is situated in the inner mitochon-
drial membrane. The intervention did not clearly modulate the
transcriptional regulation of ACADS, in spite of its activity on C4-
fatty acids. Next to mediating fatty acid transport, the rate of
Figure 2. Differentially expressed genes in Pathways for fatty acid metabolism, TCA cycle and the electron transport chain. This
Figure was merged from 3 individual Local Mapps in Genmapp.
doi:10.1371/journal.pone.0006759.g002
Table 2. Fold changes of q-PCR and microarray analysis for 7
genes of interest.
Gene Micro-array (fc) q-PCR (fc)
Acadm 1.12 1.11
Gpx3 1.25 1.15
Gpx1 1.13 1.07
Ndufv1 1.20 0.91
Ndufa3 1.13 1.13
Gsr 1.11 0.93
doi:10.1371/journal.pone.0006759.t002
Effects of Butyrate in Humans
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of acetyl-CoA. This can be prevented by the observed increased
transcription of both citrate synthase (CS), which drives the citric
acid cycle, and by mitochondrial 3-hydroxy-3-methylglutaryl-CoA
synthase (HMGCS2). HMGCS2 converts acetyl-CoA to ketone
bodies [46] thereby preventing the accumulation of acetyl-CoA
[47]. In humans, HMGCS2 is expressed in liver, skeletal muscle,
heart, pancreas, testis and colon[48]. In rats, the expression of
HMGCS2 in the colon depends on the amount of butyrate
produced by the intestinal microbiota [49,50]. The mediation of
fatty acid transport and HMGCS2 together with the increased
ACADM and ACADVL expression suggests that butyrate is able
to regulate the rate of fatty acid oxidation.
Butyrate is known to inhibit proliferation in colonic tumor cells
and cell lines [7,12] but to stimulate proliferation in healthy
colonic epithelial cells [51,52]. This is often referred to as ‘‘the
butyrate paradox’’ [7]. It was suggested previously that HMCGS2
is involved in the inhibiting effect of butyrate on cell proliferation
[53]. HMGCS2 expression in colonic epithelial cells is butyrate
dependent and correlates with the capacity of the colon for
ketogenesis and the fatty acid oxidation rate [49,50]. One
explanation for the butyrate paradox is that healthy cells have
an efficient butyrate metabolism resulting in low intracellular
butyrate concentrations and therefore a decrease in capacity to
inhibit growth [53]. In colon cancer cell lines, b-oxidation and
HMGCS2 expression are impaired [53]. The decreased oxidation
rate of butyrate may result in increased intra-cellular butyrate
concentrations in tumor cells, hence causing increased histone
deacetylation and subsequently decreased proliferation. The
observation that butyrate affects proliferation is strengthened by
the finding in the present study that several genes which are known
to be involved in either proliferation, cell growth or cell size were
differentially expressed by the butyrate intervention.
Butyrate mediated the transcription of genes that are involved
in pyruvate dehydrogenase, citric acid cycle and the respiratory
chain. The gene dihydrolipoamide acetyltransferase (DLAT),
which encodes for a subunit of the pyruvate dehydrogenase
complex forming acetyl-CoA from pyruvate was upregulated.
Butyrate also increased the transcription of the genes that encode
citrate synthase (CS) and succinate dehydrogenase (SDHD).
Citrate synthase is the first enzyme of the TCA- cycle and
catalyses the condensation of oxaloacetate, a cyclic acid cycle
intermediate, and acetyl-CoA to form citrate. SDHD, which is also
directly coupled to complex two of the electron transport chain,
oxidizes succinate to fumarate as the first part of the final step of
the citric acid cycle [54]. Nicotinamide adenine dinucleotide
(NADH) and flavin adenine dinucleotide (FADH2), formed by
glycolysis, the TCA- cycle and b-oxidation, subsequently enter the
electron transport chain where the electrons are transferred along
the respiratory chain in order to form ATP. Butyrate induced
increased transcription of genes participating in all five complexes
of the respiratory chain. In complex one, the genes NDUFA3 and
NDUFV1 were significantly upregulated (and confirmed by q-
PCR). SDHD, active in complex two of the respiratory chain, was
upregulated. In total, 14 out of 72 genes that participate in the
respiratory chain were upregulated (Table S2). In conclusion,
butyrate regulated numerous genes involved in all parts of the total
energy metabolism and ATP production, which provides molec-
ular support for the general assumption that butyrate is involved in
the energy metabolism of colonic epithelial cells.
Oxidative stressis an imbalancebetween the anti-oxidant defense
network and the production of reactive oxygen species (ROS) and
reactive nitrogen species (RNS). Butyrate has previously been
shown to affect oxidative stress and inflammation [13,55].
In the present study, oxidative stress related pathways and NF-
kB signaling were shown to be affected by butyrate. More
specifically, the expression of glutathione peroxidases GPX 1 and
GPX 3 and glutathione reductase (GSR) were upregulated in the
oxidative stress pathway.
Glutathione (GSH) is used to eliminate reactive oxygen species,
a reaction that is catalyzed by glutathione peroxidase. The
glutathione disulfide (GSSG) produced in this reaction can be
converted back to GSH by the action of the enzyme glutathione
reductase (GSR)[56]. In the present study, the increased
expression of GPX1, GPX3 and GSR suggests that butyrate
induces an increased glutathione turnover capacity and an
increased antioxidant capacity. This was in line with earlier
findings from our group showing an increased GSH production
after butyrate administration [55]. GSH can also detoxify harmful
electrophils, and is catalyzed by glutathione-S-transferase (GST).
Previous studies showed that butyrate induced the expression
levels of GST [57,58]. However, we did not observe transcrip-
tional regulation of GST in the present study. The previously
reported finding that butyrate mediates the JAK/STAT signaling
pathway [59], which plays an important role in the regulation of
NO production in epithelial cells, supports the upregulation of one
of the other genes in the oxidative stress pathway in the present
study, NADH quinone oxidoreductase 1(NQO1), which also
mediates nitric oxide (NO) biosynthesis. The current observation
suggests that butyrate may increase stimulation of epithelial
proliferation, migration and apoptosis.
In an inflamed colon, reactive oxygen species (ROS) are
produced by neutrophilic granulocytes, which are associated with
increased oxidative stress as was previously reported in ulcerative
colitis and Crohn’s disease [60,61]. In the present study, the gene
encoding nuclear factor kappa beta inhibitor a (NFKBIA), was
upregulated. NFKBIA inhibits the activation of NF-kB and the
TNF-a signaling cascade, thereby potentially leading to dimin-
ished inflammation and inflammation-induced oxidative stress.
Another important biological process affected by butyrate is
proteasome degradation. This process, in which eight genes were
differentially expressed (Table S2), provides a mechanism for
degradation of (oxidatively) damaged proteins and the genes in this
pathway are associated with apoptosis, ageing and oxidative stress
[62].
Hence, butyrate regulated genes that are associated with
glutathione metabolism, inflammation, NO synthesis and protea-
some degradation, all supporting its previously demonstrated
potential to reduce inflammation and oxidative stress.
Theq-PCRanalysesconfirmedthemicroarrayresultsof4outof6
genes confirmed the microarray results, whereas two genes were
upregulated in the microarray analysis while they were downregu-
lated inthe q-PCR analysis.One gene wasnot significantlyregulated
based on the microarray results but showed a downregulation in the
q-PCR analysis. There is international consensus that the Affymetrix
microarray technology provides a reliable platform to measure gene
expression [63]. The observed differences between microarray and
q-PCR analysis are in line with earlier observations and can also be
explained by differences in probe sequence and thus target location
[63]. Because of these known problems to confirm microarray data
with q-PCR, the relevance and importance of such a comparison
should be reconsidered. Pathway analysis in combination with
stringent statistical methods provides a strong indication for the
qualityofthemicroarraymeasurement.Ifpathwayanalysisresults in
significantly regulated pathways, a number of genes cluster within
the same process, hence increasing the likelihood that the fold
changes of these individual genes, measured simultaneously, were
correct. The added value of the combination of both microarray
Effects of Butyrate in Humans
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evaluating the reliability of the outcome of the microarray analysis.
Butyrate was administered by rectal enemas, because this is a safe
and reliable way to deliver a specific amount of substrate to the distal
colon. Other techniques, such as oral intake of dietary fibers or
encapsulated butyrate, do not allow to accurately target the distal
colon invivo.The distal colonwas chosen astarget area forthe butyrate
intervention since the concentration of butyrate is lowest in this part of
the colon due to rapid fermentation of commonly ingested dietary
fibers in the proximal colon and the incidence of carcinomas and
diseases in particularly the distal part of the colon is rising [1,2].
Furthermore, a mucosal specimen of the distal colon can be obtained
much more easily compared to that of the proximal colon, without
sedation and previous bowel cleansing. The latter is of pivotal
importance in this type of studies to avoid disturbance of the
physiological conditions in the gut, leading to interference with the
effects of the intervention. Volunteers instilled the enemas in the
evening prior to sleeping in order to obtain an optimal spread of the
butyrate in the distal colon and to minimize the risk of leakage. The
spread of enemas was studied previously in patients with ulcerative
colitis [64–67]. In a pilot study in healthy volunteers, we confirmed,
using enemas containing radio actively labeled Indium, that the
spread of the 60 ml enemas used in the present study reached beyond
the sigmoid colon [unpublished data]. More research is needed on the
actual concentration of butyrate at different locations in the human
colon in vivo to optimize the dose and method of administration.
This study showed for the first time in healthy volunteers the
effect of butyrate treatment on the gene transcriptional level in the
distal colon. Previously observed beneficial effects of butyrate from
patient, animal- and in vitro studies are also induced in healthy
subjects. The results presented in this study provide new leads to
study the mechanisms involved in the effects of butyrate in
humans. Future studies should be planned in order to study and
optimize the functional consequences of butyrate or dietary fiber
in the colon.
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Table S1 This table shows the GO-annotations, ranked by Z-
score
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